The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
The James Madison Memorial Building is located between First and Second Streets on Independence Avenue SE. The building was constructed from 1971 to 1976, and serves as the official memorial to James Madison, a Founding Father and the fourth President of the United States. The Madison Building is also home to the United States Copyright Office and to the Mary Pickford Theater, the "motion picture and television reading room" of the Library of Congress. The theater hosts regular free screenings of classic and contemporary movies and television shows.
=== Diagnostics === There is interest in its use in wearable technology. Sweat can be sampled and sensed non-invasively and continuously using electronic tattoos, bands, or patches. However, sweat as a diagnostic fluid presents numerous challenges as well, such as very small sample volumes and filtration (dilution) of larger-sized hydrophilic analytes. Currently the only major commercial application for sweat diagnostics is for infant cystic fibrosis testing based on sweat chloride concentrations.
=== Temperature === Conversion of both CO and CO2 to CH4 starts at a catalyst temperature below 300°C, but the conversion is incomplete and peak tailing is evident. At around 340°C, conversion is complete, as indicated by area measurements, but some tailing limits the peak height. At 360-380°C, tailing is eliminated and there is little change in peak height up to 400°C. Operating temperatures for various methanizers range from 350-400°C. Although carbonization of CO has been reported at temperatures above 350°, it is rather a rare phenomenon.
Sources: en.wikipedia.org
Detergents, such as SDS or Tween-20, which are used to break open cells and release the DNA. Protease enzymes, such as Proteinase K, which are used to digest proteins that may be binding to the DNA. Phenol and chloroform, which are used to separate the DNA from other cellular components. Ethanol or isopropanol, which are used to precipitate the DNA. Salt, such as NaCl, which is often used to help dissolve the DNA and maintain its stability. EDTA, which inactivates enzymes such as nucleases by chelating (binding) metals ions needed as cofactors. Tris-HCL, which is used to maintain the pH at the optimal condition for DNA extraction.
=== Housing === In 2026, Pritzker proposed the "Building Up Illinois Developments" (BUILD) plan for approval by the Illinois General Assembly to amend the fiscal year 2027 state budget, which involves amending the Illinois Municipal Code to relax zoning restrictions, permit greater volume of single-family housing units on lots, legalize the construction accessory dwelling units—granny flats, backyard cottages and above-garage apartments—on residential properties, and prohibit the enactment of minimum parking requirements for certain types of residential and mixed-use housing typically set by municipal governments, in order to spur housing construction and development to reduce costs and meet the state's housing supply needs. The plan also prevents building codes from prohibiting the construction of single-stair residential suites. On February 19, 2026, Representative Kam Buckner introduced the plan in the Illinois House of Representatives as HB5626. Accordingly, Pritzker's administration also authorized the Illinois Housing Development Authority to provide down-payment assistance through the IDHAccess Home program, calculated at 6% of the purchase price up to $15,000, for qualified, low- to middle-income homebuyers who do not own a home or have not owned one in the preceding three years, as well as veterans.
ISBN 0-89966-613-2 OCLC 68043161 Cooke, James J. The All-Americans at War: The 82nd Division in the Great War, 1917–1918. Westport, Conn: Praeger, 1999. ISBN 0-275-95740-3 OCLC 39210048 Cooksey, Jon. Crossing the Waal: The US 82nd Airborne Division at Nijmegen. Barnsley: Pen and Sword Military, 2005. ISBN 1-84415-228-6 OCLC 57200754 Covington, Henry L. A Fighting Heart, An Unofficial Story of the 82nd Airborne Division. Fayetteville, NC: T. Davis, 1949. OCLC 4139070 Dawson, Buck. Saga of the All American. Atlanta: Albert Love Enterprises, 1946. OCLC 3595988 Francois, Dominique. 82nd Airborne Division 1917–2005. Bayeux: Heimdal, 2006. ISBN 2-84048-215-0 OCLC 64967339 Gavin, James M. On to Berlin: Battles of an Airborne Commander, 1943–1946. New York: Viking Press, 1978. ISBN 0-670-52517-0 OCLC 3204743 Grey, Stephen. Into the Viper's Nest: The First Pivotal Battle of the Afghan War. Minneapolis: Zenith Press, 2010. ISBN 0-7603-3897-3 OCLC 548583278 Heilman, William H. A Pilot's Tale: Flying Helicopters in Vietnam. Hooks, Tex.?: William H. Heilman, 2008. ISBN 1-4357-1185-8 OCLC 671642623 Hoyt, Edwin Palmer. The Invasion Before Normandy: The Secret Battle of Slapton Sands. Lanham, MD: Scarborough House, 1999. ISBN 0-8128-8562-7 OCLC 41712914 Imai, Kesaharu. Grenada : 25 October to 2 November 1983. Tokyo: World Photo Press, 1984. OCLC 16348601 Langdon, Allen. Ready: The History of the 505th Parachute Infantry Regiment, 82nd Airborne Division, World War II. [Fort Bragg, N.C.]: The Division, 1986. OCLC 16221387 Lebenson, Leonard.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.